Sirtex completes recruitment for SIR-Spheres trial

Sirtex Medical (ASX:SRX) has completed patient recruitment for its latest trial of its SIR-Spheres microspheres, its targeted radiation therapy for liver cancers.

The FOXFIRE Global trial will evaluate combining SIR-Spheres Y-90 resin microspheres with standard of care chemotherapy in first-line metastatic colorectal cancer patients with inoperable liver metastases.

It will compare the results of combining microspheres with chemotherapy against chemotherapy alone.

Combined with its SIRFLOX and FOXFIRE clinical studies, over 1000 patients have been recruited globally. Over 200 of these have been enrolled in the FOXFIRE Global study.

The primary overall survival endpoint from the combined trials is expected to be available during the first half of 2017.

“We are delighted to have completed recruitment of our FOXFIRE Global clinical study on schedule, with the total number of patients recruited ahead of initial expectations under the study design,” Sirtex CEO Gilman Wong said.

“This study, when combined with the [others], will generate sufficient statistical power to determine whether SIR-Spheres microspheres in combination with existing chemotherapy can increase OS in a clinically significant manner in these patients versus chemotherapy alone.”

Sirtex Medical (ASX:SRX) shares were trading 1.52% higher at $28.04 as of around 2.30 pm on Friday.